Hospitals, Medical Professionals, ACO's

Performance Based Agreements

Does your hospital, medical group or Accountable Care Organization participate in performance-based contracts with third party payers?  

Does it seem like the probability of receiving bonus payments under Medicare Advantage arrangements are completely out of your control? 

Let's take a quick look at some industry statistics. 

  • According to the CDC, adverse drug events or ADE's
    • account for nearly $3.5 billion each year in health care costs
    • cause nearly 700,000 emergency room visits and hospital re-admissions
    • represents nearly 12% of all heath care costs (approximately $290 billion)

While the concept of integrated care is not new and the advent of electronic health record platforms has enhanced connectivity the costs outlined above need to be addressed.  With the shift of responsibility to health care organizations for these escalating costs, a proactive approach to reducing ADE's is almost imminent.  

There are several genes encoding enzymes, drug transporters, carriers, and membrane channels that are essential for major processes of drug absorption, digestion, metabolism, and excretion. For example, one of the largest family of genes, known as the Cytochrome P450 (CYP), are involved in the metabolism of  >70% of prescription drugs.  Genetic sequence variations in these genes can lead to altered protein function, potentially resulting in poor outcomes such as ineffective therapy and/or adverse side effects.  

 

population health

Advanced Genetics Lab offers, at no costs to your organization, a patient risk assessment report.  We assess NDC data for your risk-based contract patients and can easily determine potential ADE exposure.   We can also assess the financial impact this is having on your health system and correlated reduction once patients are under a managed medication treatment plan incorporating PGx assay assessment.  To set up a free assessment just click here. 

 

transitional care

One of the main reasons for a lack of medication adherence and compliance can be traced to either a perceived or actual impact on treatment.   About 59% of drugs most commonly cited in ADE studies are processed by enzymes with genes known to have poor metabolizer variant versus 7% of a random selection of top selling drugs (JAMA 286:2270 2001).